Healio: Marked health status improvement with mavacamten in obstructive hypertrophic cardiomyopathy

May 17, 2021

The cardiac myosin inhibitor mavacamten substantially improved health status in patients with symptomatic obstructive hypertrophic cardiomyopathy, with benefits observed early after treatment, according to new data from EXPLORER-HCM.

Presenting new health status data from the trial at the American College of Cardiology Scientific Session, John A. Spertus, MD, MPH, with Saint Luke’s Mid America Heart Institute and the Lauer/Missouri Endowed Chair and professor at UMKC, said mean Kansas City Cardiomyopathy Questionnaire overall summary score differences favoring mavacamten (MyoKadria) were amongst the largest he has observed for any medication, eclipsed only by structural heart interventions.

“There is a very impressive improvement in the symptoms, function and quality of life of [mavacamten]-treated patients and it is really impressive that, when on the medicine, patients get the benefit; when they come off the medicine, benefit goes away,” Spertus told Healio. “It supports a direct cause-and-effect relationship between treatment and improved health status.”

Read the full Healio article: Marked health status improvement with mavacamten in obstructive hypertrophic cardiomyopathy

Related Content

EXPLORER-HCM Trial shows dramatic improvements in patients with common genetic heart condition, comes after decades of no new treatments
Saint Luke’s Mid America Heart Institute announced the results of a clinical trial that will impact patient care and improve quality of life for patients suffering from the most common genetic heart condition.
Saint Luke’s Researchers Again Take Center Stage at Global Cardiology Conference
Saint Luke’s Mid America Heart Institute to share detailed trial results at American College of Cardiology Scientific Session May 15-17.
Dr. John Spertus, director of health outcomes research at Saint Luke's Mid America Heart Institute
Saint Luke’s Innovation Week Profile: Dr. John Spertus
Dr. John Spertus didn't choose medicine; medicine chose him.